Major pharmaceutical breakthroughs have improved health results for years, yet recent evidence suggests GLP-1 treatments like Ozempic and Wegovy might affect a larger scope: the consumer market. Designed initially to treat diabetes and now often recommended for weight reduction, these medications do more than impact bodily wellness and physique.
They are also molding group actions—such as dietary preferences, buying habits, physical activity, self-perception, and choices—with key ramifications for industry executives.
